Additional validation experiments with western blot showed dampened Lck phosphorylation by Dasatinib in T cells (Figure 4C), which further helps explain the depletion of tumor-infiltrating T cells by a month-long Dasatinib treatment in the CPPSML CRPC model [16]. This evidence concerns the gene LCK and neoplasm.